Literature DB >> 27171579

Transgenic Models in Retinoblastoma Research.

Rohini M Nair1, Geeta K Vemuganti1.   

Abstract

Understanding the mechanism of retinoblastoma (Rb) tumor initiation, development, progression and metastasis in vivo mandates the use of animal models that mimic this intraocular tumor in its genetic, anatomic, histologic and ultrastructural features. An early setback for developing mouse Rb models was that Rb mutations did not cause tumorigenesis in murine retinas. Subsequently, the discovery that the p107 protein takes over the role of pRb in mice led to the development of several animal models that phenotypically and histologically resemble the human form. This paper summarizes the transgenic models that have been developed over the last three decades.

Entities:  

Keywords:  Knockout models; LHβ-Tag; Retinoblastoma; Transgenic models; Tumorigenesis

Year:  2015        PMID: 27171579      PMCID: PMC4847202          DOI: 10.1159/000370157

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  47 in total

1.  Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma.

Authors:  T G Murray; D B Roth; J M O'Brien; W Feuer; N Cicciarelli; A M Markoe; E Hernández; B J Smith; J J Windle
Journal:  Arch Ophthalmol       Date:  1996-11

2.  Enumeration of the simian virus 40 early region elements necessary for human cell transformation.

Authors:  William C Hahn; Scott K Dessain; Mary W Brooks; Jessie E King; Brian Elenbaas; David M Sabatini; James A DeCaprio; Robert A Weinberg
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

4.  Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.

Authors:  Shin J Kang; Chandrasekar Durairaj; Uday B Kompella; Joan M O'Brien; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2009-08

5.  Topotecan combination chemotherapy in two new rodent models of retinoblastoma.

Authors:  Nikia A Laurie; Jonathan K Gray; Jiakun Zhang; Mark Leggas; Mary Relling; Merrill Egorin; Clinton Stewart; Michael A Dyer
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

6.  Neuronal and glial properties of a murine transgenic retinoblastoma model.

Authors:  T Kivelä; I Virtanen; D M Marcus; J M O'Brien; J L Carpenter; E Brauner; A Tarkkanen; D M Albert
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

7.  Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.

Authors:  Maria-Elena Jockovich; M Livia Bajenaru; Yolanda Piña; Fernando Suarez; William Feuer; M Elizabeth Fini; Timothy G Murray
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

8.  Embryonic retinal tumors in SV40 T-Ag transgenic mice contain CD133+ tumor-initiating cells.

Authors:  Lalita Wadhwa; Wesley S Bond; Laszlo Perlaky; Paul A Overbeek; Mary Y Hurwitz; Patricia Chévez-Barrios; Richard L Hurwitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-08       Impact factor: 4.799

9.  Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences.

Authors:  B O Williams; E M Schmitt; L Remington; R T Bronson; D M Albert; R A Weinberg; T Jacks
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

10.  Intravitreal and subconjunctival melphalan for retinoblastoma in transgenic mice.

Authors:  Nisha V Shah; D G Pham; T G Murray; C Decatur; E Hernandez; Nikesh N Shah; M Cavalcante; S K Houston
Journal:  J Ophthalmol       Date:  2014-03-10       Impact factor: 1.909

View more
  7 in total

1.  Kif14 overexpression accelerates murine retinoblastoma development.

Authors:  Michael O'Hare; Mehdi Shadmand; Rania S Sulaiman; Kamakshi Sishtla; Toshiaki Sakisaka; Timothy W Corson
Journal:  Int J Cancer       Date:  2016-06-24       Impact factor: 7.396

Review 2.  The chick eye in vision research: An excellent model for the study of ocular disease.

Authors:  C Ellis Wisely; Javed A Sayed; Heather Tamez; Chris Zelinka; Mohamed H Abdel-Rahman; Andy J Fischer; Colleen M Cebulla
Journal:  Prog Retin Eye Res       Date:  2017-06-28       Impact factor: 21.198

Review 3.  Heterogeneity in retinoblastoma: a tale of molecules and models.

Authors:  Sonya Stenfelt; Maria K E Blixt; Charlotta All-Ericsson; Finn Hallböök; Henrik Boije
Journal:  Clin Transl Med       Date:  2017-11-09

Review 4.  Beyond What Your Retina Can See: Similarities of Retinoblastoma Function between Plants and Animals, from Developmental Processes to Epigenetic Regulation.

Authors:  Estephania Zluhan-Martínez; Vadim Pérez-Koldenkova; Martha Verónica Ponce-Castañeda; María de la Paz Sánchez; Berenice García-Ponce; Sergio Miguel-Hernández; Elena R Álvarez-Buylla; Adriana Garay-Arroyo
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

5.  A short-term chick embryo in vivo xenograft model to study retinoblastoma cancer stem cells.

Authors:  Rohini M Nair; Narayana V L Revu; Sucharita Gali; Prathap Reddy Kallamadi; Varsha Prabhu; Radhika Manukonda; Harishankar Nemani; Swathi Kaliki; Geeta K Vemuganti
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

6.  Commentary: A short-term chick embryo in vivo xenograft model to study retinoblastoma cancer stem cells.

Authors:  Krishnakumar Subramanian
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

7.  A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma.

Authors:  Duangporn Saengwimol; Duangnate Rojanaporn; Vijender Chaitankar; Pamorn Chittavanich; Rangsima Aroonroch; Tatpong Boontawon; Weerin Thammachote; Natini Jinawath; Suradej Hongeng; Rossukon Kaewkhaw
Journal:  Sci Rep       Date:  2018-10-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.